Correlation Between Kronos Bio and Cyclacel Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Kronos Bio and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kronos Bio and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kronos Bio and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on Kronos Bio and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kronos Bio with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kronos Bio and Cyclacel Pharmaceuticals.

Diversification Opportunities for Kronos Bio and Cyclacel Pharmaceuticals

-0.08

Correlation Coefficient

Kronos Bio  Cyclacel Pharmaceuticals

Good diversification

The 3 months correlation between Kronos and Cyclacel is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding Kronos Bio and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and Kronos Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kronos Bio are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of Kronos Bio i.e., Kronos Bio and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between Kronos Bio and Cyclacel Pharmaceuticals

Given the investment horizon of 90 days Kronos Bio is expected to generate 1.12 times more return on investment than Cyclacel Pharmaceuticals. However, Kronos Bio is 1.12 times more volatile than Cyclacel Pharmaceuticals. It trades about 0.19 of its potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about -0.16 per unit of risk. If you would invest  85.00  in Kronos Bio on September 16, 2024 and sell it today you would earn a total of  13.00  from holding Kronos Bio or generate 15.29% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Kronos Bio  vs.  Cyclacel Pharmaceuticals

Kronos Bio

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Kronos Bio are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Kronos Bio may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Preferred Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Kronos Bio and Cyclacel Pharmaceuticals

The main advantage of trading using opposite Kronos Bio and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kronos Bio position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.

The idea behind Kronos Bio and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.